| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $28.0M | +53.0% |
| Cost of Revenue | $76.6M | -6.4% |
| R&D Expense | $1.6M | -71.9% |
| SG&A Expense | $75.3M | -19.4% |
| Operating Income | -$125.5M | +22.8% |
| Pre-tax Income | -$137.7M | +0.1% |
| Income Tax | $0 | -100.0% |
| Net Income | -$137.7M | +0.2% |
| EPS (Basic) | -$5.86 | -651.3% |
| EPS (Diluted) | -$5.86 | -651.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.6M | -68.0% |
| Accounts Receivable | $12.1M | +1110.0% |
| Inventory | $9.6M | +0.0% |
| Current Assets | $86.4M | -42.0% |
| Total Assets | $861.2M | -2.8% |
| Current Liabilities | $150.0M | -4.3% |
| Long-term Debt | $746.1M | +67.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$106.4M | -6.6% |
| Investing Cash Flow | -$23.9M | +92.9% |
| Financing Cash Flow | $81.9M | +2924.1% |
| Total Liabilities |
| $598.1M |
| +17.4% |
| Stockholders' Equity | $263.1M | -30.1% |